je.st
news
Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer
2015-01-13 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. & INDIANAPOLIS Combinations of KEYTRUDA (pembrolizumab) with Alimta (pemetrexed), Cyramza (ramucirumab), or necitumumab to be explored KENILWORTH, N.J. & INDIANAPOLIS--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the US and Canada, and Eli Lilly and Company (NYSE:LLY) announced today an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials: Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Justin Holko, 908-740-1879orLillyEli Lilly and CompanyKeri McGrath, 317-277-3768Communications Managermcgrath_happeks@lilly.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: LLY Exchange: NYSE read more
Tags: enter
research
agreement
types
Category:Biotechnology and Pharmaceuticals